MLTX: Reports Phase 3 VELA Results
MoonLake announces Phase 3 VELA program week 52 results showing 67.2% of sonelokimab-treated patients achieving HiSCR75 in moderate-to-severe hidradenitis suppurativa
Reported Sunday, MoonLake Announces Phase 3 VELA Program Week 52 Results Showing 67.2% Of Sonelokimab-Treated Patients Achieving HiSCR75 In Moderate-To-Severe Hidradenitis Suppurativa